October 10, 2024
Getting drugs to the brain is difficult. The very thing designed to protect the brain’s environment — the blood-brain barrier (BBB), tightly packed cells that prevent […]
October 9, 2024
TOPLINE: Increased exposure to nitrogen dioxide (NO2) and particulate matter with a diameter of ≤ 2.5 µm (PM2.5) is associated with an increased risk for Parkinson’s […]
October 8, 2024
PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s disease (PD), was shown to significantly reduce disease burden in two […]
October 8, 2024
A strategy developed by Canadian researchers for encouraging older patients with insomnia to wean themselves from sleeping pills and improve their sleep through behavioral techniques is […]
October 8, 2024
(Reuters) -Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer’s disease after it failed to meet the main goal of […]
October 7, 2024
COPENHAGEN — Serum glial fibrillary acidic protein (sGFAP) is quickly maturing as a biomarker to predict disability in patients with multiple sclerosis (MS), but it will […]
October 4, 2024
TOPLINE: Erenumab, injected monthly at 140 mg, can effectively induce remission of nonopioid medication overuse headache (MOH) in patients with chronic migraine within 6 months. The […]
October 4, 2024
An international expert panel has developed consensus guidelines to help clinicians navigate multiple sclerosis (MS) diagnosis in atypical populations — specifically children and older adults. Here’s […]
October 4, 2024
TOPLINE: Older adults who experience falls are at a higher risk of developing dementia within a year. The study found that 10.6% of patients who fell […]